Blog
RSS FeedPosted by Michael Wonder on 03 Jul 2023
EU-HTA: G-BA coordinates parallel scientific consultations for manufacturers from September
3 July 2023 - From 2025, a systematic evaluation of clinical studies for new medicinal products and medical devices will ...
Posted by Michael Wonder on 13 Jun 2023
Planned revision of EU pharmaceutical legislation: early market access and robust evidence need not remain a contradiction in terms
13 June 2023 - On 26 April, the EU Commission presented a proposal for the revision of pharmaceutical legislation in ...
Posted by Michael Wonder on 13 May 2023
Orphan drugs: early generation of evidence urgently needed
10 May 2023 - A team led by IQWiG authors, together with Rita Banzi from the Italian Mario Negri Institute, analysed ...
Posted by Michael Wonder on 02 May 2023
Trastuzumab deruxtecan: benefits also in HER2 low breast cancer
2 May 2023 - For patients with advanced HER2 low breast cancer, IQWiG sees an additional benefit that is partly considerable ...
Posted by Michael Wonder on 17 Apr 2023
Olaparib in metastatic prostate cancer: added benefit for certain patients
17 April 2023 - Younger treatment naïve patients benefit. No relevant data were presented for previously treated patients. ...
Posted by Michael Wonder on 15 Mar 2023
Zanubrutinib in chronic lymphocytic leukaemia: additional benefit for certain patients
15 March 2023 - For adults with relapsed/refractory chronic lymphocytic leukaemia who have not yet received a BTK or BCL2 inhibitor, ...
Posted by Michael Wonder on 02 Mar 2023
Efficient RCTs with real world data for benefit assessments: accelerating evidence-based care
2 March 2023 - Together with colleagues from the Belgian HTA agency KCE, three employees of IQWiG in the BMJ are ...
Posted by Michael Wonder on 16 Feb 2023
Thomas Kaiser becomes the new head of IQWiG
16 February 2023 - The current head of the IQWiG department for drug assessment succeeds Jürgen Windeler, who is retiring after ...
Posted by Michael Wonder on 02 Feb 2023
Advanced breast cancer: now a significant added benefit for trastuzumab deruxtecan
2 February 2023 - New results from an early-initiated study show advantages in overall survival. ...
Posted by Michael Wonder on 26 Jan 2023
Draft methods (version 7.0): IQWiG is extending the comment period
26 January 2023 - The new deadline is 28 February 2023. ...
Posted by Michael Wonder on 17 Jan 2023
Vutrisiran in hereditary transthyretin amyloidosis: hint of minor added benefit
17 January 2023 - Vutrisiran is approved for the treatment of patients with hereditary transthyretin amyloidosis with stage 1 or ...
Posted by Michael Wonder on 03 Jan 2023
Pertuzumab and pertuzumab with trastuzumab in breast cancer: now a minor additional clinical benefit
2 January 2023 - Advantages in overall survival and in relapses often only become apparent after a long period of ...
Posted by Michael Wonder on 20 Dec 2022
Meta-analyses with very few studies: different beta-binomial models in comparison
16 December 2022 - A team led by IQWiG authors compared the usual beta-binomial model for meta-analysis of small study pools ...
Posted by Michael Wonder on 11 Dec 2022
Clinical Disease Activity Index (CDAI) first choice when assessing treatment effects
9 December 2022 - A team led by IQWiG authors systematically compares instruments for measuring the treatment effects of disease-modifying ...
Posted by Michael Wonder on 08 Dec 2022
IQWiG updates its General Methods
6 December 2022 - Revision of the cost-benefit assessment and addition of the concept of application-accompanying data collection: Comments on ...